Share This

Public company info - Genscript Biotech Corporation , 01548.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Genscript Biotech Corporation, 01548.HK - Cash Flow 2022-12 2021-12 2020-12 2019-12 2018-12 2017-12 2016-12 2015-12 2014-12 2013-12 2012-12
Net Cash Flow from Operating Activities -129,353 -138,005 -158,671 -23,083 293,334 26,519 40,152 21,838 16,109 13,418 11,210
Net Cash Flow from Return on Investments & Servicing of Finance 8,401 1,926 -3,480 11,957 3,968 -1,778 266 60 -325 -301 -107
　Interest Received 10,440 3,502 4,382 12,691 4,017 857 276 60 86 36 63
　Interest Paid -2,039 -1,576 -1,330 -734 -49 0 -10 0 -411 -337 -170
　Dividend Received 0 0 0 0 0 0 0 0 0 0 0
　Dividend Paid 0 0 -6,532 0 0 -2,635 0 0 0 0 0
　Others 0 0 0 0 0 0 0 0 0 0 0
Taxes (Paid) / Refunded 660 -711 4,526 -18,829 -1,939 -6,008 -7,153 -2,262 -3,989 -1,430 -2,083
Net Cash Flow from Investing Activities -443,296 -212,548 -100,166 -208,633 -181,666 -36,451 -8,315 -4,099 -9,114 -10,914 -7,317
　Additions to Fixed Assets -201,303 -131,336 -121,879 -110,371 -70,839 -29,215 -8,553 -6,711 -7,355 -8,418 -9,529
　Disposal of Fixed Assets 88 272 56 364 0 134 0 0 3 0 2
　Increase in Investments -375,324 -264,134 -432,794 -1,332,256 -104,481 -4,877 71 -4,087 -30,447 -24,308 -19,380
　Decrease in Investments 187,894 240,126 450,540 1,231,408 0 131 0 6,810 32,400 20,854 21,633
　Net Cash Flow with Related Parties -8,781 -194 372 -5,582 4,323 1,739 0 -8,178 8,172 33 0
　Others -45,870 -57,282 3,539 7,804 -10,669 -4,363 167 8,067 -11,887 925 -43
Net Cash Flow before Financing Activities -563,588 -349,338 -257,791 -238,588 113,697 -17,718 24,950 15,537 2,681 773 1,703
Net Cash Flow from Financing Activities 419,317 902,141 630,735 -2,778 257,322 4,674 8,497 65,168 806 2,325 71
　New Loans 33,062 26,041 52,921 27,248 10,502 0 0 0 7,776 7,594 4,937
　Loans Repayment -7,388 -74,935 -30,595 -20,405 0 0 -1,237 0 -15,142 -5,302 -4,866
　Fixed Income/Debt Instruments 0 0 157,936 0 0 0 0 0 0 0 0
　Repayment of Fixed Income/Debt Instruments 0 0 0 0 0 0 0 0 0 0 0
　Equity Financing 423,307 951,229 459,561 3,735 253,972 2,935 9,734 73,346 0 0 0
　Net Cash Flow with Related Parties -8,781 -194 372 -5,582 4,323 1,739 0 -8,178 8,172 33 0
　Others -20,883 0 -9,460 -7,774 -11,475 0 0 0 0 0 0
Increase(Decrease) in Cash & Cash Equivalents -144,271 552,803 372,944 -241,366 371,019 -13,044 33,447 80,705 3,487 3,098 1,774
Cash & Cash Equivalents at Beginning of Year 1,180,971 629,058 252,397 494,558 123,857 136,464 103,720 25,637 22,457 18,660 16,778
Net Cash Flow due to Change in Exchange Rate/Others -12,701 -890 3,717 -795 -318 437 -703 -2,622 -307 699 108
Cash & Cash Equivalents at End of Year 1,023,999 1,180,971 629,058 252,397 494,558 123,857 136,464 103,720 25,637 22,457 18,660
Currency U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar U.S. Dollar
Unit
Auditor's Opinion 1 1 1 1 1 1 1 1 0 0 0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.